The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival after osimertinib dose-reduction, discontinuation in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
 
Adam Barsouk
No Relationships to Disclose
 
Omar Elghawy
No Relationships to Disclose
 
Austin Yang
No Relationships to Disclose
 
Alec Heidlauf
No Relationships to Disclose
 
Connie Yu
No Relationships to Disclose
 
David Yang
No Relationships to Disclose
 
Lucy Wang
No Relationships to Disclose
 
Martin Kurian
No Relationships to Disclose
 
Keshav Goel
No Relationships to Disclose
 
Lynn Rushkin
No Relationships to Disclose
 
Anran Huang
No Relationships to Disclose
 
Lauren Reed-Guy
No Relationships to Disclose
 
Benjamin Bleiberg
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Janssen Oncology
 
Lova Sun
Consulting or Advisory Role - Bayer; Genmab/Seagen; Genzyme; MJH Life Sciences; Regeneron
Research Funding - Abbvie (Inst); Blueprint Medicines (Inst); Erasca, Inc (Inst); Frontier Medicines (Inst); Immunocore (Inst); IO Biotech (Inst); Merus (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst)
 
Aditi Singh
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Precision HEOR (I)
Research Funding - Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst)
 
Roger Cohen
Consulting or Advisory Role - Actuate Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Cantargia AB (Inst); Chugai Pharma (Inst); F-Star Biotechnology (Inst); Innate Pharma (Inst); Xencor (Inst)
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novocure; Pfizer; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)
 
Melina Marmarelis
Stock and Other Ownership Interests - Johnson & Johnson; Merck
Honoraria - AstraZeneca; Blueprint Medicines; Janssen Oncology; Novocure; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Janssen Oncology; NEUVOGEN; Regeneron
Research Funding - AstraZeneca (Inst); Genentech (Inst); Ikena Oncology (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Regeneron
 
Corey Langer
Honoraria - AstraZeneca; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; Ariad (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
Other Relationship - Amgen; Lilly; OncoCyte; Peregrine Pharmaceuticals; Summit Therapeutics; Synta